ElectroCore Inc

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ElectroCore reports record revenue growth and strategic expansion plans

ElectroCore's Q1 2024 earnings call showcased impressive revenue growth, strong gross margins, and successful product launches, underlining the company's market resilience and innovation capabilities. With a focus on strategic expansion and profitability, ElectroCore is well-positioned for sustained growth and market leadership.
While facing challenges in managing R&D expenses and optimizing product returns, ElectroCore's commitment to operational efficiency and market diversification mitigates potential risks. The company's emphasis on employee contributions and customer relationships reinforces its competitive edge and customer loyalty.
By capitalizing on opportunities to expand product offerings, enter new markets, and drive innovation, ElectroCore can unlock significant growth potential and solidify its position as a key player in the neuromodulation industry. Navigating challenges through strategic decision-making and market differentiation will be crucial for ElectroCore's future success.

ElectroCore reports record revenue and margin growth in Q2 2024

ElectroCore's Q2 2024 earnings call showcased exceptional financial performance, marked by record revenue, improved margins, and a notable reduction in net loss.
The company's strengths lie in its revenue growth, product innovation, and solid financial position, while facing challenges in certain product sales and market competition.
Opportunities for ElectroCore include expanding product reach, exploring new therapeutic areas, and leveraging its strong cash position for strategic investments and growth.
Overall, ElectroCore's performance reflects resilience and potential for sustained growth in the healthcare industry, supported by a strong financial foundation and innovative product pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROCKAWAY, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled “Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial” in Cephalalgia, the official journal of the International Headache Society (IHS). The paper reports the results of a randomized, double-blind, sham-controlled trial conducted at twenty-seven sites across the United States. Originally designed and powered to randomize 400 patients, the study was closed early due to COVID-19 after enrolling 231 subjects.

electroCore Announces Publication of PREMIUM II Trial of gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine

electroCore is a developer and marketer of non-invasive vagus nerve stimulation devices for the treatment of pain. The Company's gammaCore nVNS device is approved for cluster headache, and recently received label expansion for PH and HC in adults.

electroCore: Pioneering Bioelectronic Medicine

ROCKAWAY, NJ, Dec. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into agreements with Melidonia Health Services (Melidonia), Cyrus Medical Technologies (Cyrus), and Express Medical Solutions LLC. (Medexsol) to serve as the exclusive distributors of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Cyprus, the United Arab Emirates and Oman, and Saudi Arabia and Bahrain, respectively.

electroCore, Inc. Provides Update on Global Distribution Partners

ROCKAWAY, NJ, Dec. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United Kingdom. The site, which can be found at www.gammacore.co.uk, requires patients to complete a healthcare questionnaire in order to purchase a gammaCore Sapphire™, non-invasive vagus nerve stimulator (nVNS) device online.

electroCore, Inc. Announces The Launch of a New Online Shop in the United Kingdom

ROCKAWAY, NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on the ongoing clinical research to assess the potential of gammaCore (non-invasive vagal nerve stimulation; nVNS) to treat Post Traumatic Stress Disorder (“PTSD”).

electroCore, Inc. Provides Update on nVNS to Treat Post Traumatic Stress Disorder

ROCKAWAY, NJ, Dec. 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,191,953 to the Company, relating to the treatment of stroke symptoms.

electroCore Announces New Patent for Stroke and TIA Treatment

Bally's

Alphatec Hlds

TRACON Pharmaceuticals

Insider sales are generally a sign the market is about to drop, but not everyone's selling. Here are five companies with insider buying.

5 Stocks Insiders Are Still Buying (Even As Others Cash Out)

ROCKAWAY, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be available for virtual one-on-one meetings at the Canaccord Genuity MedTech & Diagnostics Forum. The conference is taking place virtually November 18, 2021. Details are as follows:

electroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum

electroCore, Inc. (ECOR) CEO Daniel Goldberger on Q3 2021 Results - Earnings Call Transcript

Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020

electroCore Announces Third Quarter 2021 Financial Results

ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2021 after the close of the market on Thursday, November 4, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.

electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th

Health Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescents Health Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescents

electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine

ROCKAWAY, NJ, Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today, September 30, 2021 at 12:40 PM eastern time.

electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference

Endo International

AB Corporate Bond ETF

Powerbridge Technologies Co Ltd

Solid Biosciences

Uxin Ltd - ADR

WiMi Hologram Cloud

Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.

7 Best Penny Stocks to Buy on the Nasdaq for October

ROCKAWAY, NJ, Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore SapphireTM in patients admitted to the hospital for treatment of COVID-19; is available on MedRxiv and has been submitted for peer review. This study was an investigator-initiated trial conducted at the Hospital Clínico Universitario de Valencia, Spain.

electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients

ROCKAWAY, NJ, Sept. 15, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods integrated with, or coupled to, smartphones that allow patients to self-treat medical conditions, such as migraine headache, by electrical non-invasive stimulation of nerves. The ‘102 patent is the 8th US patent issued to ECOR in the company's mobile connectivity platform, with additional US and International matters pending.

electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices

ROCKAWAY, NJ, Sept. 14, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug Administration (FDA) of the company's submission to expand the label of gammaCore nVNS to include the treatment of Paroxysmal Hemicrania (PH) and Hemicrania Continua (HC) in adults.

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

ROCKAWAY, NJ, Aug. 31, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Conference. The conference is taking place virtually from September 13 - 15, 2021. Details for the presentation are as follows:

electroCore to Present at the HC Wainwright 23rd Annual Global Investment Conference

ROCKAWAY, NJ, Aug. 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LLC. (Red One). The partnership will further expand availability of electroCore's gammaCore platform in the federal marketplace.

electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC.

electroCore, Inc. (ECOR) CEO Dan Goldberger on Q2 2021 Results - Earnings Call Transcript

The stock price of electroCore, Inc. (NASDAQ: ECOR) increased by over 25% during intraday trading. This is why it happened.

ECOR Stock Price Increases 25% Intraday: Why It Happened

Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially. Company to host a conference call and webcast today, August 5, 2021 at 4:30 pm ET Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially. Company to host a conference call and webcast today, August 5, 2021 at 4:30 pm ET

electroCore Announces Second Quarter 2021 Financial Results

A combination of a large total addressable market, regulatory clearance, strong partnerships and effective product has Ladenburg Thalmann analysts bullish on electroCore, Inc. (NASDAQ:ECOR). The electroCore Analyst: Jeffrey Cohen initiated coverage on electroCore with a Buy rating and $3 price target.

ElectroCore Analyst: Nerve Stimulation Market Opportunity Is Large

Ladenburg Thalmann has initiated coverage of ElectroCore Inc (NASDAQ: ECOR) with a Buy rating and $3 price target, implying an upside of around 190%. The Company's gammaCore Sapphire device is currently commercially available both in the U.S. and outside the U.S., and analyst Jeffrey Cohen believes that electroCore should be valued in comparison with other innovative healthcare and bioelectric companies, he tells investors.

ElectroCore Stock Is Trading Higher As Ladenburg Initiates Coverage With $3 Price Target, Buy Rating

ROCKAWAY, NJ, July 27, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.

News for ElectroCore Inc Stock (ECOR)